The American Journal of Managed Care: Focus Turns to Unmet Needs in ITP, Related Autoimmune Diseases After Rilzabrutinib Approval: David Kuter, MD, DPhil Focus Turns to Unmet Needs in ITP, Related Autoimmune Diseases After Rilzabrutinib Approval: David Kuter, MD, DPhil ITP (immune thrombocytopenia) is an autoimmune disorder where the body attacks its own blood platelets. This leads to a decrease in the number of platelets and consequently can cause a number of ... Immune thrombocytopenia (ITP) is a chronic autoimmune disorder associated with platelet destruction and increased bleeding risk, substantial economic burden, and impairment of health-related quality ...
The most pressing questions in ITP involve finding a cure and developing treatments safe for use during pregnancy. I think the major challenges in ITP are several. One, and I think the [rilzabrutinib] ... FierceBiotech: ASH: Novartis details ianalumab's phase 3 win in rare blood disease Fierce Biotech: In a first, a CAR-T cell therapy drives 3 autoimmune diseases into remission in a single patient A CAR-T cell therapy has successfully treated not one, not two, but three different autoimmune diseases at once in a patient, providing further proof of the modality’s promise in the disease area as a ...
